Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - KERYX BIOPHARMACEUTICALS INC | exhibit312q3201810qa.htm |
| EX-31.1 - EXHIBIT 31.1 - KERYX BIOPHARMACEUTICALS INC | exhibit311q3201810qa.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________________
FORM 10-Q/A
(Amendment No. 1)
x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2018
OR
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to .
Commission File Number 000-30929
___________________________________________________
KERYX BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 13-4087132 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
One Marina Park Drive, 12th Floor
Boston, Massachusetts 02210
(Address including zip code of principal executive offices)
(617) 466-3500
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files): Yes x No ¨:
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act
Large accelerated filer | x | Accelerated filer | ¨ | ||
Non-accelerated filer | ¨ (Do not check if a smaller reporting company) | Smaller reporting company | ¨ | ||
Emerging growth company | ¨ | ||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: ¨
Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ¨ No x
There were 120,375,926 shares of the registrant’s common stock, $0.001 par value, outstanding as of October 31, 2018.
EXPLANATORY NOTE
This Amendment No. 1 on Form 10-Q/A (the “Amendment”) is an amendment to Keryx Biopharmaceuticals, Inc.’s (the “Registrant”) Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2018 (the “Report”) filed with the Securities and Exchange Commission on November 8, 2018. The Registrant is filing this Amendment for the sole purpose of correcting an inadvertent transposition error on the cover page of the Report in the number of shares of the Registrant’s common stock, $0.001 par value, outstanding as of October 31, 2018, which should be 120,375,926 instead of 102,375,926. In addition, the Registrant is also including Exhibits 31.1 and 31.2 with this Amendment. This Amendment does not alter any other part of the content of the Report and does not affect the information originally set forth in the Report, the remaining portions of which have not been amended.
ITEM 6. EXHIBITS
The following exhibits are included with this Amendment:
Exhibit Number | Exhibit Description | |
31.1 | ||
31.2 | ||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KERYX BIOPHARMACEUTICALS, INC. | |||
Date: November 9, 2018 | By: | /s/ Scott A. Holmes | |
Scott A. Holmes Chief Financial Officer Principal Financial and Accounting Officer | |||